logo
Halcyon Launches First-Ever Dedicated Ransomware Threat Intelligence Bounty Program

Halcyon Launches First-Ever Dedicated Ransomware Threat Intelligence Bounty Program

Business Wire21-04-2025

AUSTIN, Texas--(BUSINESS WIRE)-- Halcyon, the leading platform designed from day one to defeat ransomware, today announced its new Threat Research Incentive Program (TRIP), the first-ever dedicated ransomware threat intelligence bounty initiative. With the launch of TRIP, Halcyon is committing $250,000 to reward independent researchers and ransomware hunters for responsibly disclosing threat intelligence on ransomware operations.
TRIP will accelerate anti-ransomware capabilities by sourcing novel intelligence from trusted researchers while rewarding them for their technical contributions to ransomware defense.
Ransomware continues to cripple businesses of all sizes, across every industry. In the first five weeks of 2025 alone, ransomware attacks increased 149% year over year. Across the globe, independent researchers and threat hunters uncover new ransomware samples, attacker infrastructure, and evasion techniques every day, providing critical information in the fight against ransomware. However, much of their work is done for free and often goes unrecognized. TRIP aims to change that.
'It's simple - our mission is to eradicate ransomware by all means necessary. We are calling on independent researchers and ransomware hunters to join us in our fight to stop attacks,' said Jon Miller, CEO and Co-Founder, Halcyon. 'Whether you're a full-time reverse engineer, OSINT specialist, or passionate about defending others — Halcyon wants to work with you. Together, we will fuel an unstoppable global alliance of defenders focused on defeating ransomware at scale and change the ransomware game.'
TRIP will accelerate anti-ransomware capabilities by sourcing novel intelligence from trusted researchers while rewarding them for their technical contributions to ransomware defense. Researchers who provide valuable intelligence via technical deep-dive write ups and direct SIEM or Dashboard panel access or exports will be rewarded based on a tiered structure:
Tier 1: Novel details on ransomware groups, RaaS platforms, affiliate attackers, initial access brokers, and other key players in ransomware operations will be rewarded up to $10,000 per accepted submission.
Tier 2: Novel details on attacker tooling, infrastructure, evasion techniques, and other TTPs will be rewarded up to $5,000 per accepted submission.
Tier 3: Novel details on droppers, loaders, packers, and other tooling will be rewarded up to $3,000 per accepted submission.
Tier 4: Novel details on indicators of compromise (IOCs) or behavior chains will be rewarded up to $1,000 per accepted submission.
To ensure the quality and success of the program, a dedicated Halcyon team will follow strict guidelines to vet all research contributions before accepting the submission for compensation. Individuals who appear on an OFAC list are not eligible to participate in the program. Additionally, all researchers must affirm sourcing and independent status.
To learn more about Halcyon and its TRIP program, please visit: www.halcyon.ai/trip
About Halcyon
Halcyon is the only cybersecurity company that eliminates the business impact of ransomware. Modern enterprises rely on Halcyon to prevent ransomware attacks, eradicating cybercriminals' ability to encrypt systems, steal data, and extort companies. Backed by an industry-leading warranty, the Halcyon Anti-Ransomware Platform drastically reduces downtime, enabling organizations to quickly and easily recover from attacks without paying ransoms or relying on backups.
Learn more at www.halcyon.ai.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum
Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum

Business Wire

time7 minutes ago

  • Business Wire

Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ('Simulations Plus', 'SLP'), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O'Connor, Chief Executive Officer, will be participating in the Citizens Medical Devices and Healthcare Services Forum taking place in Boston, Massachusetts. Mr. O'Connor will host one-on-one meetings with institutional investors on Tuesday, June 17, 2025. For more information about the events or questions about registration, interested parties should reach out to their contacts at Citizens. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2023 ESG update.

NEUPATH HEALTH ANNOUNCES VOTING RESULTS FROM THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS
NEUPATH HEALTH ANNOUNCES VOTING RESULTS FROM THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS

Business Wire

time22 minutes ago

  • Business Wire

NEUPATH HEALTH ANNOUNCES VOTING RESULTS FROM THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS

TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), ('NeuPath' or the 'Company'), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced the voting results from its Annual General and Special Meeting of Shareholders (the 'Meeting') held on June 11, 2025 and the grant of stock options ('Options') and restricted share units ('RSUs'). All figures are in Canadian dollars, unless otherwise noted. The results of the director elections were as follows: The shareholders of the Company also voted: (i) to reappoint Ernst & Young LLP, Chartered Professional Accountants, Licensed Public Accountants, as auditors of the Company for the ensuing year, (ii) to approve the Company's amended and restated stock option plan in the form attached as Schedule 'A' to the management information circular dated April 22, 2025 prepared in connection with the Meeting (the 'Stock Option Plan'), and (iii) to approve the Company's amended and restated restricted share unit plan in the form attached as Schedule 'B' to the management information circular dated April 22, 2025 prepared in connection with the Meeting (the 'RSU Plan'). Amendments to the RSU Plan At the Meeting, the Company proposed the adoption of the RSU Plan which was amended to increase the maximum number of common shares of the Company ('Common Shares') issuable thereunder from 3,000,000 Common Shares to 5,000,000 Common Shares. At the Meeting, 99.38% shareholder votes cast were in favour of adopting the RSU Plan. Issuance of Stock Options and Restricted Share Units On June 12, 2025, NeuPath granted an aggregate of 150,000 Options to non-executive directors of the Company at an exercise price of $0.26 per share, with an expiry date of June 12, 2032. The Options are subject to time-based vesting and will fully vest on June 12, 2026. The terms of the Options granted are in accordance with the Stock Option Plan. In addition, on June 12, 2025, the Company granted an aggregate of 60,000 RSUs to the same non-executive directors of the Company. The RSUs are subject to time-based vesting in accordance with the policies of the TSX Venture Exchange. RSUs granted will fully vest on June 12, 2026. The terms of the RSUs granted are in accordance with the RSU Plan. About NeuPath NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to patients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit

Cybin to Participate in the H.C. Wainwright 6 th Annual Neuro Perspectives Conference
Cybin to Participate in the H.C. Wainwright 6 th Annual Neuro Perspectives Conference

Business Wire

time23 minutes ago

  • Business Wire

Cybin to Participate in the H.C. Wainwright 6 th Annual Neuro Perspectives Conference

TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright 6 th Annual Neuro Perspectives Conference, taking place June 16-17, 2025. Mr. Drysdale's fireside chat will be available on demand beginning on Monday, June 16, 2025, at 7:00 a.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company's investor relations website on the Events & Presentations page. About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store